ArticleCancers2021
Cathepsin S Evokes PAR
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- MMP1 and PRSS23 induce PARCommunications biology · 2026Article
- Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma.BMC oral health · 2026Article
- Nanoparticle-mediated antagonism of sustained endosomal signaling of the calcitonin receptor-like receptor provides enhanced and persistent relief of oral cancer pain.Biomaterials · 2026Article
- The causal relationship between cathepsins and ankylosing spondylitis: a two-sample Mendelian randomization study.Therapeutic advances in musculoskeletal disease · 2026Article
- Probing the activity of cysteine cathepsins in inflammatory bowel diseases.Scientific reports · 2025Article
- The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy.Functional & integrative genomics · 2025Review
- Oral Cancer and Sleep Disturbances: A Narrative Review on Exploring the Bidirectional Relationship.Cancers · 2025Review
- PARBiomaterials · 2025Article
- Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- Measurement of the Association of Pain with Clinical Characteristics in Oral Cancer Patients at Diagnosis and Prior to Cancer Treatment.Journal of pain research · 2024Article
- Cathepsin S (CTSS) in IgA nephropathy: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target.Frontiers in immunology · 2024Article
- The CaScience signaling · 2023Article
- Chemical Tools to Image the Activity of PAR-Cleaving Proteases.ACS bio & med chem Au · 2023Review
- Article
- Cathepsins in oral diseases: mechanisms and therapeutic implications.Frontiers in immunology · 2023Review
- Resolving the conflicts around Par2 opposing roles in regeneration by comparing immune-mediated and toxic-induced injuries.Inflammation and regeneration · 2022Article
- Oral cancer patients experience mechanical and chemical sensitivity at the site of the cancer.BMC cancer · 2022Article
- Oral Cancer Cells Release Vesicles that Cause Pain.Advanced biology · 2022Article
- Advances in Head and Neck Cancer Pain.Journal of dental research · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Nguyen Huu TuBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Kenji InoueBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Elyssa ChenBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Bethany M AndersonDepartment of Biochemistry and Pharmacology, Bio21 Institute, University of Melbourne, Parkville, VIC 3052, Australia.ORCID 0000-0002-1663-1099
Caroline M SawickiBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.ORCID 0000-0001-9295-9849
Nicole N ScheffBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.ORCID 0000-0002-5587-4990
Hung D TranBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Dong H KimBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Robel G AlemuBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Lei YangBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
John C DolanBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Cheng Z LiuPathology Department, New York University (NYU) Langone Health, New York, NY 10016, USA.
Malvin N JanalDepartment of Epidemiology and Health Promotion, New York University (NYU) College of Dentistry, New York, NY 10010, USA.ORCID 0000-0003-1098-9687
Rocco LatorreDepartment of Molecular Pathobiology, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Dane D JensenBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.ORCID 0000-0001-6540-2375
Nigel W BunnettDepartment of Molecular Pathobiology, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Laura E Edgington-MitchellBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Brian L SchmidtBluestone Center for Clinical Research, Department of Oral and Maxillofacial Surgery, New York University (NYU) College of Dentistry, New York, NY 10010, USA.
Center for Clinical Research (United States) · USNYU Langone Health · USThe University of Melbourne · AUCancer Research Center · USNew York University · USYork University · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1MProtease/PAR2/TRPV4 Axis and Oral Cancer PainR01DE026806 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2022
$3.9MEndosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4MTrafficking-Dependent Signaling of Pain by Protease-Activated ReceptorsR01DK118971 · NIDDK · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2021
$3.2MIntratumor co-delivery of DNA and RNA to relieve cancer painR01DE029694 · NIDCR · NEW YORK UNIVERSITY · PI SCHMIDT, BRIAN L, YAMANO, SEIICHI · 2021 to 2025
$2.9MDissecting the heterogeneity of oral cancer painK23DE029844 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SAWICKI, CAROLINE · 2021 to 2025
$525kMultispectral imaging & analysis of intact tissue sections w/ the Perkin Elmer VectraS10OD021747 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOOMIS, CYNTHIA A · 2016 to 2016
$359kNCI NIH HHS P30 CA016087NIDCR NIH HHS K23 DE029844NIDCR NIH HHS R01 DE026806NIDCR NIH HHS R01 DE029694NIDDK NIH HHS R01 DK118971NIH HHS DE026806NIH HHS DE029951NIH HHS DK118971NIH HHS NS102722NIH HHS S10 OD021747NINDS NIH HHS R01 NS102722
Abstract
Oral squamous cell carcinoma (SCC) pain is more prevalent and severe than pain generated by any other form of cancer. We previously showed that protease-activated receptor-2 (PAR
Indexed as
cancer paincathepsin Soral canceroral squamous cell carcinomapainPAR2protease-activated receptor-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.